ViiV Wants FDA, Not NAD, To Handle Dispute Over Its Dovato HIV Drug Ads

Gilead Sciences, Inc. turned to the National Advertising Division rather than the US Food and Drug Administration when it sought action against ViiV Healthcare’s Dovato HIV drug advertising claims. But ViiV declined to participate in NAD’s review so NAD has referred the matter to both FDA and the Federal Trade Commission.

Prior to the referral, NAD conducted an inquiry into Gilead’s challenge of ViiV’s ad claims. In its